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OBJECTIVE: The objective of this systematic review is to determine whether or not 
bimatoprost 0.03% improves satisfaction in patients at least 12 years old with eyelash 
hypotrichosis. 
 
STUDY DESIGN: Systematic review of three multicenter, double-masked, randomized, parallel 
group studies, all published in English between 2015 and 2016.   
 
DATA SOURCES: All three studies used in this review were researched via PubMed and were 
published in peer-reviewed journals. 
 
OUTCOMES MEASURED: Patient satisfaction was measured using the Eyelash Satisfaction 
Questionnaire (ESQ) in all three studies. 
RESULTS: Wirta et al. (J Clin Aesthet Dermatol. 2015;8:11–20.) found a statistically 
significant relationship between bimatoprost 0.03% and satisfaction with a p=0.004. Borchert et 
al. (Clin Ophthalmol. 2016;10:419-29. doi:10.2147/OPTH.S89561) did not indicate a p-value but 
78.2% of subjects treated with bimatoprost 0.03% and 65% of subjects in the control were found 
to have an increase in satisfaction of eyelash growth at the end of the study.  The study 
conducted by Glaser et al. (Br J Dermatol. 2015;172(5):1384-94.) did not find a statistically 
significant relationship between bimatoprost 0.03% and satisfaction with p=0.25. 
CONCLUSIONS: The results of these studies show that the objective question remains 
inconclusive in regard to increasing patient satisfaction after the use of bimatoprost 0.03% as 
only one out of the three studies showed a statistically significant relationship.  Further studies 
should be conducted with researchers not employed by the pharmaceutical company who 
manufactures the product.   
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INTRODUCTION 
Eyelash hypotrichosis is a condition that is characterized by reduced hair growth, specifically 
of the eyelashes.  Hypotrichosis is often used interchangeably with the term alopecia areata 
which is a condition of the skin that causes sudden hair loss in various parts of the body.1  The 
presentation of eyelash hypotrichosis is an inadequate amount of hair at the margin of the upper 
eyelids while alopecia areata presents as hair loss on the body, scalp, eyebrows or eyelashes.  
Eyelashes are considered terminal hair, in which the hair is coarse, thick and pigmented, versus 
vellus hair which is the soft, short and non-pigmented hair, such as those found on the face.2  The 
function of eyelashes is very versatile.  Eyelashes provide a barrier, protecting the eyes from 
foreign bodies and perspiration by triggering the corneal reflex if touched.  Eyelashes are also 
cosmetically appealing, and the length of eyelashes signifies beauty and femininity in most 
cultures while increasing the attractiveness of a person.2  
Causes of eyelash hypotrichosis include genetics, chemotherapy induced, advanced age or 
trauma to the face including trichotillomania.2  Eyelash hypotrichosis is a common side effect 
among chemotherapy drugs.  Since hair cells are rapidly dividing, chemotherapy drugs destroy 
those cells, causing hair loss.3  The prevalence of eyelash hypotrichosis is unknown, although, 
chemotherapy induced hair loss, including eyelashes will be the result of approximately sixty-
five percent of patients undergoing chemotherapy.4 As stated previously, eyelashes have a 
physical and cosmetic component attached to them and eyelash hypotrichosis or alopecia areata 
may lead to a negative impact on the patient’s quality of life including an impairment in psycho-
social functioning as well as negatively affecting the self-image of a person.5  
Unfortunately, the number of healthcare visits for eyelash hypotrichosis has not been 
identified; however, there is an estimated 2.4 million doctor office visits in the United States are 
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for alopecia areata.6  The cost of eyelash hypotrichosis has not been identified, but the out-of-
pocket costs associated with alopecia areata is approximately $1,354 per year.7  This cost 
includes hair appointments, vitamins, insurance deductibles, office visits, transportation and wigs 
for patients with alopecia areata.7 
To date, there is no known definitive treatment for eyelash hypotrichosis. Additionally, there 
is no known cure or FDA-approved treatments for alopecia areata. There are, however, off label 
uses for corticosteroids, calcineurin inhibitors, immunotherapies and hair-growth-stimulating 
solutions for alopecia areata. 8   Many patients have reported these treatments as ineffective 
while some patients could not tolerate the side effects, therefore, needing additional treatment 
options.8  Corticosteroids are the most common type of medication prescribed for alopecia 
areata, which includes oral, topical and injectable.  This treatment worked well for some patients, 
but many have stated that corticosteroids worked very little to none.8  Fortunately, for patients 
with eyelash hypotrichosis, there is now an FDA-approved treatment, bimatoprost 0.03%. 
Bimatoprost is a synthetic prostamide F2 alpha analogue and its use for eyelash hypotrichosis 
was empirically discovered in patients being treated with bimatoprost for increased intraocular 
pressure in patients with open-angle glaucoma.9  As stated previously, many patients reported the 
treatments above were ineffective for alopecia areata, but the same has not been reported for 
bimatoprost 0.03%.  
OBJECTIVE:  
The objective of this systematic review is to determine whether or not bimatoprost 0.03% 
improves satisfaction in patients at least 12 years old with eyelash hypotrichosis. 
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METHODS 
This systematic review analyzes three randomized control trials (RCTs) to assess patient 
satisfaction of bimatoprost 0.03% for the treatment of eyelash hypotrichosis compared with a 
vehicle in patients at least 12 years old.  
All three articles were found through PubMed using the key words bimatoprost and eyelash.  
The articles selected for review were published in English and were published in peer-reviewed 
journals.  Each article was selected based on its relevance to the clinical question and if they 
included patient orientated outcomes (POEMS).  The inclusion criteria consisted of all articles 
being published in English and dated 2008 or later.  Studies were excluded from this review if 
published in another language other than English, dated before 2008 or if bimatoprost was used 
for other indications.  All three articles used p-value, EER, CER, ARR, NNT, ABI and RBI 
statistics.  Please see Table 1 for the outline of demographics and characteristics of each study. 
 For this selective evidence-based medicine review, the author chose three randomized 
control studies (RCTs) that were selected, reviewed and analyzed based on population, 
intervention, comparison groups and outcomes measured.  This review included a population of 
patients at least 12 years of age with idiopathic or chemotherapy induced eyelash hypotrichosis.  
The intervention in these studies involved an application of bimatoprost 0.03% ophthalmic 
solution to the margin of the upper eyelids.  The patients receiving bimatoprost 0.03% were 
compared to the experimental group in which patients applied a vehicle to the margin of the 
upper eyelids.   Each of the three studies measured the satisfaction of the patients in both the 
treatment and control group using the Eyelash Satisfaction Questionnaire (ESQ) which is a self-
reported assessment of satisfaction. 
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Table 1. Demographics & Characteristics of Included Studies 














130 ≥ 18  ≥ 18 yo w/ chemo-
induced eyelash 
hypotrichosis Tx’d for 
Stage I-IIIA solid 
tumors w/ curative 
intent or rcv’d front-
line tx for stage I - II 
DLBCL or HL; 
resolution of chemo 
related AE’s except 
for hair loss; 
completed chemo 4-
16 wks prior to study 
baseline; Had Eastern 
Cooperative 
Oncology group 
performance status of 
0 or 1 & no evidence 
of mets or anticipated 
need for further 
chemo during study 
period 
If they did not 
have a GEA 
score of 1 or 2, or 
if they did not 
have a ESQ score 























12-17 yo Healthy, 
Chemo or alopecia 
areata induced 
eyelash hypotrichosis; 
GEA score 1-3, visual 
acuity of 20/100; IOP 
≤20mmhg; completed 




















130 ≥ 18  ≥ 18 yo w/ score of 1-
2 on GEA and ESQ; 
visual acuity of 
20/100; IOP ≤20 
mmhg; Inadequate 
eyelashes after 
chemo, tx for stage 
1,2 or 3a cancer; last 
chemo was 4-16wks 
prior to baseline, 
considered ca free 
Any eye disease 
or abnormality; 
hx of eye surgery  
14 Bimatoprost 
0.03% 
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OUTCOMES MEASURED 
 The outcomes measured in this selective evidence-based review were based on patient-
reported questionnaires that were completed throughout and at the end of the bimatoprost 0.03% 
ophthalmic treatment.  
 In all three studies, patient satisfaction was measured using the Eyelash Satisfaction 
Questionnaire (ESQ).  This is a patient-reported outcome measure that consists of 23 questions 
measured on a five-point scale.  The scale included: 1- very much disagree, 2- disagree, 3- 
neutral, 4- agree, 5- very much agree.  The 23 questions consisted of three domains which 
assessed various outcomes.  The Wirta et al.5 study focused on Domain 2 of the ESQ which 
assessed satisfaction with subjective attributes of eyelashes such as attractiveness, confidence 
and professionalism.11  In this study, subjects were assessed with the ESQ before and after 
treatment.  In a pediatric study by Borchert et al.,10 only subject’s aged 12-17 assessed their 
eyelashes with the ESQ as well.  These subjects were evaluated at screening and months 1-5 of 
the study.10 The last study by Glaser et al.11 also measured patient satisfaction using the ESQ 
five-point scale Domain 2 before and after treatment.  
RESULTS 
This systematic review analyzed three randomized control studies to determine if 
bimatoprost 0.03% can increase satisfaction in patients at least 12 years old who have eyelash 
hypotrichosis.  Each study consisted of a treatment group with bimatoprost 0.03% applied to the 
upper eyelid margins and a control group with a vehicle applied to the upper eyelid margins. 
In the Wirta et al.5 study, 130 patients with chemotherapy induced eyelash hypotrichosis 
were randomized with a web response system of an automatic interactive voice to either 
bimatoprost 0.03% (n=96) or a vehicle group (n=34).  Patients, investigators and their staff were 
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blind to treatment assignment for the entire treatment period.  Each subject was asked to place 
one drop of treatment or vehicle to a sterile, single-use applicator and then brush it on the upper 
eyelid margins once every evening.  Excluded subjects were those with unequal Global Eyelash 
Assessment (GEA) scores for the left and right eyelashes, uncontrolled systemic disease or 
known ocular disease.  Eye examinations such as intraocular pressure and iris color were 
conducted throughout the study.  Conjunctival hyperemia was the most common adverse 
reaction of bimatoprost, followed by punctate keratitis, upper respiratory tract infection and eye 
pruritus, respectively.  The study reported one death following the first administration of 
bimatoprost, but investigators attribute this due to an elective surgery and not related to the study 
medication.5 
Wirta et al.5 compared baseline and 6 months ESQ Domain 2 scores of subjects and 
increased satisfaction was considered if there was a ≥ 3-point improvement. At the end of the 6 
months, Wirta et al.5 found that there was an increase in satisfaction in 46.9% (46 patients) 
versus 18.2% (6 patients) for bimatoprost 0.03% and vehicle, respectively.  The p-value was 
considered to be statistically significant at p=0.004 and NNT was calculated to be 4. Table 2 
includes detailed calculations for this study. 
Table 2. NNT Calculations For Satisfaction of Bimatoprost 0.03% To Improve Eyelash 
Hypotrichosis By Wirta et al.5 











1.576 0.287 4 0.004 
 
Borchert et al.10 studied 62 pediatrics aged 12-17 years old with eyelash hypotrichosis 
who were randomized 2:1 to either receive bimatoprost 0.03% (n=42) or vehicle (n=20). 
Patients, investigators and their staff were blind to treatment assignment for the entire treatment 
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period of 5 months.  Subjects or their guardians were instructed to place one drop of treatment or 
vehicle to a sterile, single-use applicator and then brush it on the upper eyelid margins once 
every evening.  Subjects were excluded from this study if there was gross asymmetry of eyelash 
prominence between right and left eyes, uncontrolled systemic disease, suspected or known 
trichotillomania or ocular disease appreciated. Adverse effects were monitored at each study 
entry and physical exams performed including eye examinations of IOP, visual acuity and iris 
color at baseline, and months 1 and 4.10 
This study used Pearson’s chi-square and dichotomized the ESQ score responses into two 
groups: satisfied and not satisfied/neutral.10  The results showed that mean scores improved from 
baseline in both treatment groups for satisfaction.10  This study showed that 78.2% (33 patients) 
of subjects in the treatment group were satisfied versus 65% (13 patients) of subjects in the 
control group. There was no p-value calculated for subject satisfaction and NNT was calculated 
to be 8. Table 3 includes detailed calculations for review.  
Table 3. NNT Calculations For Satisfaction of Bimatoprost 0.03% To Improve Eyelash 
Hypotrichosis By Borchert et al.10 












0.207 0.135 8 Not 
calculated 
 
Glaser et al.11 analyzed 129 subjects with chemotherapy-induced eyelash hypotrichosis 
who were randomized to either receive bimatoprost 0.03% (n=96) or vehicle (n=33).  All 
patients, investigators and staff were blind to treatment assignment for the entire study.  Subjects 
were instructed to place one drop of treatment or vehicle to a sterile, single-use applicator and 
then apply it to the upper eyelid margins once every evening.  In this study, subjects were 
excluded if they had any eye abnormality or disease or a history of eye surgery.  Primary efficacy 
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was based on at least a 3-point increase from baseline in the total score for ESQ domain 2.  
Glaser et al.11 found an increase in satisfaction in 47.9% (46 patients) versus 36.4% (12 patients) 
for bimatoprost 0.03% and vehicle, respectively.  The p-value was considered to not be 
statistically significant at p=0.25 and NNT was calculated to be 9. Table 4 includes detailed 
calculations. 
Table 4. NNT Calculations For Satisfaction of Bimatoprost 0.03% To Improve Eyelash 
Hypotrichosis By Glaser et al.11 













0.315 0.115 9 0.25 
 
DISCUSSION 
 This systematic review analyzes the results of bimatoprost 0.03% for patients with 
eyelash hypotrichosis.  Only one of the three studies show statistical significance for the use of 
bimatoprost 0.03% in patients with eyelash hypotrichosis. In the Wirta et al.5 study, p= 0.004 is 
statistically significant and suggestive of increased satisfaction of eyelash growth with the use of 
bimatoprost 0.03%.  In the Borchert et al.10 study, no p-value was calculated, but 78.2% of 
subjects in the experimental group and 65% of subjects in the control group expressed 
satisfaction after treatment of bimatoprost 0.03%.  These percentages were used to calculate the 
NNT.  Based upon no provided p-value and the small NNT compared against a small sample 
size, there is not enough information to conclude whether or not this study led patients to 
increased satisfaction.  On the other hand, the Glaser et al.11 study was found to not be 
statistically significant with p=0.25.   
 Currently, bimatoprost 0.03% is marketed by only one pharmaceutical company, 
Allergan which is sold under the name, Latisse.  Since Latisse is used for cosmetic purposes 
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only, insurance companies do not cover the product.  Patients can purchase Latisse out of pocket 
with a prescription for a monthly cost of approximately $120.00.12  At this cost, most patients 
may not be able to afford this monthly price. According to Banaszek,12 patients with glaucoma 
using Lumigan, should not use Latisse as it would double the dose of bimatoprost 0.03%.  This is 
because Lumigan and Latisse are the same exact drug, just packaged and administered 
differently.12   
Acknowledging limitations to these studies is very important. In all three studies, subjects 
were instructed to apply bimatoprost 0.03% every evening in the same fashion.  If subjects did 
not follow these instructions closely, the results could have been skewed. In the Wirta et al.5 
study, 125 subjects out of a total of 130 subjects had a history of breast cancer.  Since most 
subjects in the Wirta et al.5 study were found to have breast cancer, the results of this study may 
have had a different outcome if the type of cancer was more diverse.  Additionally, there is 
overlap between the researchers for all three studies and this may limit the generalizability of the 
results. 
CONCLUSIONS 
 The results from this selective evidence-based review indicate that bimatoprost 0.03% 
increases patient satisfaction in only one out of the three studies.  Based upon this, the answer to 
the objective question remains inconclusive in regard to increasing patient satisfaction and 
further research should be conducted.  The outcomes could have been affected by drug 
adherence and correct application of bimatoprost 0.03%.  Subjects or their parents were expected 
to apply the treatment every evening in a specific fashion.  The outcomes may have also been 
affected by the researchers as each study disclosed that they were consultants, investigators or 
employees of Allergan, the pharmaceutical company that produces Latisse.  Future research of 
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bimatoprost 0.03% for eyelash hypotrichosis should be conducted without any affiliation to 
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